R-Tech Ueno: Announcement on Collaborative Development of Therapeutic Agent for Cerebral Infarction Utilizing VAP-1 Inhibitor (RTU-009) with Autonomous University of Barcelona and Vall d’Hebron Institute of Research

TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ: 4573) R-Tech Ueno, Ltd. has announced plans to conduct collaborative research with Autonomous University of Barcelona (UAB) and Vall d’Hebron Institute of Research (VHIR), in Catalonia (Spain) to develop a novel VAP-1 inhibitor (Development code: RTU-009) for treatment of cerebral infarction. RTU-009 is a novel VAP-1 inhibitor, having an anti-inflammatory and neuroprotective effect. It is confirmed that RTU-009 has a neuroprotective effect similar to